Our mission is to improve patient outcomes at a reduced cost by applying artificial intelligence to diagnostic imaging. We believe that current cardiovascular diagnostics are often either expensive, burdensome to the patient, or not sufficiently accurate. Medical imaging offers an economically efficient and non-invasive method for capturing patient health information, but additional tools are needed to realize its full diagnostic power. Our software is part of that solution, and we will continue to develop additional applications to support sustainable, enhanced patient care.
What is now Elucid Bioimaging began studies in 2009 with a mission to better understand the underlying cause of heart attacks and strokes: subclinical atherosclerosis. After years of promising studies, Elucid sought to translate these findings into a usable clinical tool to deliver better care and help reduce the number of heart attacks and strokes. The tool had to be accurate, efficient, and cost effective. After years of development, Elucid released vascuCAP® to bring this knowledge to the market and support patient care across the globe. Elucid continues to innovate and develop novel, AI-enabled solutions to healthcare’s toughest challenges.
In addition to our SaaS offering for vascuCAP®, Elucid also offers quantitative imaging services to evaluate the severity of vascular disease, in particular, atherosclerosis, and assess longitudinal therapeutic response to investigational therapeutic agents to vascular disease